Alterity 20-F: Going Concern, A$37.3M Cash, and FDA-Aligned Phase 3 Path for ATH434
ATHE sits 71% above its 52-week low of $2.66.
Summary
Alterity's FY2026 20-F discloses going concern language, A$37.3M cash (5.2 quarters runway), a completed 1-for-50 reverse split, and FDA alignment on a single pivotal Phase 3 trial for ATH434 in MSA.
Key Events · Earnings and Guidance · ATHE
-
Going Concern Disclosure
Financial statements prepared on a going concern basis contingent on funds raised during FY2026; net loss of A$23.4M and operating cash outflow of A$22.5M for the year ended June 30, 2026.
-
Cash Runway
Cash and cash equivalents of A$37.3M as of June 30, 2026, providing approximately 5.2 quarters of runway at current burn rates.
-
Reverse Split Completed
1-for-50 reverse stock split completed May 29, 2026, reducing ordinary shares outstanding from 9.13B to 217.5M; ADS ratio adjusted from 600 to 12 ordinary shares per ADS.
-
New Equity Incentive Plan
2026 Employee Incentive Securities Plan approved May 29, 2026, authorizing issuance of up to 21,750,833 ordinary shares (10% of issued shares); 3,000,000 options granted to directors at A$1.00 exercise price.
Analysis · ATHE · Life Sciences
Alterity's annual report confirms the company is a going concern only because of funds raised during FY2026, with a net loss of A$23.4M and operating cash outflow of A$22.5M. Cash of A$37.3M funds roughly 5.2 quarters of runway. The filing also confirms the 1-for-50 reverse split and a new 10% equity incentive plan. On the positive side, the FDA End-of-Phase 2 meeting minutes received July 7, 2026, confirm a registrational pathway for ATH434 in MSA, with a single pivotal trial plus confirmatory evidence potentially sufficient for approval.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.4% of the 1304 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $4.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.2M. The 52-week trading range was $2.66 to $5.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.